AYOXXA develops the LUNARIS(TM) beads‑on‑a‑chip multiplex platform to generate high‑quality proteomics data from very small sample volumes and to enable scalable quantitative validation of disease‑relevant biomarkers. The company commercializes a growing portfolio of ready‑to‑use biomarker assays with a focus on inflammation and immune‑response biology and supports translational research from laboratory models to clinical studies. The newly closed financing will provide runway for approximately three to five years and is intended to fund global commercialization across Europe, the US and Asia. The round was led by Prosnav Capital, which the company says will provide direct access to Asian markets through its regional network. As part of the transaction AYOXXA appointed a new management team to drive accelerated commercial growth, naming Dr. Albrecht Läufer CEO and Markus Fehr designated co‑CEO. Former CEO Rodney Turner will advise on the US market, and Dr. Markus Zumbansen will continue as CSO and CTO. AYOXXA is based in Cologne, Germany, and was originally a startup of the National University of Singapore; it also has a US office. Ayoxxa Biosystems is a biotechnology company based in Cologne, Germany, with operations in Singapore. It has developed a proprietary technology platform for multiplex protein analysis. Led by CEO and co-founder Dr. Andreas Schmidt and newly named CFO Andreas Richter, the company is scaling production. The firm intends to use recent funding to continue its production ramp-up and accelerate global commercial activities. In 2014 the company has raised €11.3m to date, reflecting ongoing fundraising to support growth. Its core product and platform position it to expand commercial reach in protein diagnostics and multiplex assays. Ayoxxa Biosystems has developed a proprietary technology platform for multiplex protein analysis and produces corresponding biochips. The company focuses on commercializing its biochip platform for multiplex protein assays. Ayoxxa intends to use recent funding to scale up production of its proprietary biochips and to achieve international commercial readiness. The firm completed a €9.0m Series B financing round to support those plans. Leadership includes Dr. Andreas Schmidt (CEO), Prof. Dieter Trau (CSO), Dr. Markus Zumbansen (VP R&D) and Michael Rasche (Corporate VP Global Commercial Operations). The company is based in Cologne, Germany and Singapore. AyoxxA Biosystems has developed a proprietary platform technology, its In-situ Encoded Bead-based Arrays (IEBA), for multiplexed protein analysis in very small sample volumes. The company produces bead-based biochips designed to enable precise protein measurements from limited samples. In September 2012 AyoxxA closed a €2.6M Series A financing to advance its development. The company intends to use the capital to further develop its platform technology, scale up production of its bead-based biochips and move toward commercialization. AyoxxA was founded in 2010 as a spin-off of the National University of Singapore and is led by CEO Dr. Andreas Schmidt. The company is based in Cologne, Germany, and Singapore.

Total raised

$18M

Funding rounds

4

Latest round

Series B

Latest activity

Dec 2014